Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

25. April 2018 08:00 ET | Quelle: Insmed, Inc.

Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018

BRIDGEWATER, N.J., April 25, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
29. März 2018 08:00 ET | Quelle: Insmed, Inc.

Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC

ALIS previously designated as an orphan drug, breakthrough therapy and Qualified Infectious Disease Product (QIDP) BRIDGEWATER, N.J., March 29, 2018 (GLOBE NEWSWIRE) -- Insmed...
07. März 2018 08:00 ET | Quelle: Insmed, Inc.

Insmed to Present at the Cowen and Company 38th Annual Health Care Conference

BRIDGEWATER, N.J., March 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
23. Februar 2018 07:30 ET | Quelle: Insmed, Inc.

Insmed Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

On track to file NDA before the end of March and anticipate a priority reviewExtended amikacin liposome inhalation suspension (ALIS) intellectual property protection to 2035 with issuance of ninth...
21. Februar 2018 17:26 ET | Quelle: Insmed, Inc.

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Feb. 21, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
20. Februar 2018 08:00 ET | Quelle: Insmed, Inc.

Insmed Extends ALIS Intellectual Property Protection to 2035 with Issuance of Ninth U.S. Patent

BRIDGEWATER, N.J., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
15. Februar 2018 08:00 ET | Quelle: Insmed, Inc.

Insmed to Host Fourth Quarter and Full Year 2017 Financial Results Conference Call on Friday, February 23, 2018

BRIDGEWATER, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
07. Februar 2018 16:30 ET | Quelle: Insmed, Inc.

Insmed to Present at the Leerink Partners 7th Annual Global Healthcare Conference

BRIDGEWATER, N.J., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...
26. Januar 2018 12:00 ET | Quelle: Insmed, Inc.

Insmed Announces Closing of Public Offering

BRIDGEWATER, N.J., Jan. 26, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM) announced the closing today of its previously announced public offering of its 1.75% convertible senior notes...
24. Januar 2018 17:31 ET | Quelle: Insmed, Inc.

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

BRIDGEWATER, N.J., Jan. 24, 2018 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today announced...

Vorherige Seite

Nächste Seite